MK-4827 (Niraparib): Selective PARP-1/-2 Inhibitor for BRCA-Mutant Cancer Research

Executive Summary: MK-4827 (Niraparib) is a highly selective, orally bioavailable inhibitor of PARP-1 and PARP-2, with IC₅₀ values of 3.8 nM and 2.1 nM respectively, targeting the NAD⁺ binding site and blocking DNA repair function in cancer cells [APExBIO product]. It exhibits potent antiproliferative effects in BRCA-1/2 mutant cell lines (CC₅₀ 10–100 nM), while sparing normal epithelial cells at micromolar concentrations. In vivo, MK-4827 demonstrates robust efficacy in BRCA-1 mutant and various tumor xenograft models, enhancing radiotherapy outcomes [PCI32765.com]. Recent studies indicate that combination with all-trans retinoic acid (ATRA) may overcome platinum-induced PARP inhibitor resistance in epithelial ovarian cancer (Mei et al., 2024). The compound is supplied as a small molecule (C₁₉H₂₀N₄O, MW 320.39), highly soluble in DMSO and ethanol, but insoluble in water, and is recommended for storage at -20°C [APExBIO].

Biological Rationale

Poly(ADP-ribose) polymerase (PARP) enzymes, including PARP-1 and PARP-2, are essential mediators of the DNA damage response, catalyzing poly(ADP-ribosyl)ation of nuclear proteins in the presence of DNA strand breaks [Strategic Horizons in PARP Inhibition]. These modifications facilitate recruitment of DNA repair machinery, notably in the base excision repair and single-strand break repair pathways. Tumors with homologous recombination deficiency (HRD)—commonly arising from BRCA-1 or BRCA-2 mutations—are unable to repair double-strand breaks effectively. Inhibition of PARP activity in these cells leads to synthetic lethality, selectively impairing cancer cell viability while sparing normal cells with intact HR pathways. This principle underpins the clinical and preclinical application of MK-4827 (Niraparib) as a targeted agent for BRCA-mutant and DNA repair-deficient cancers [MK-4827: Selective PARP Inhibitor]. Recent research also implicates PARP inhibition in radiosensitization and potentiation of DNA-damaging chemotherapies (Mei et al., 2024).

Mechanism of Action of MK-4827 (Niraparib), a potent and selective PARP-1/-2 inhibitor

MK-4827 (Niraparib) acts as a competitive inhibitor targeting the NAD⁺ binding pocket of PARP-1 and PARP-2. By preventing NAD⁺ substrate access, it blocks poly(ADP-ribosyl)ation, abrogating recruitment of repair proteins to damaged DNA. This results in accumulation of unrepaired single-strand breaks, which are converted to double-strand breaks during DNA replication. In BRCA-1 or BRCA-2 mutant cells, deficient in homologous recombination, these breaks are lethal, leading to cell cycle arrest and apoptosis. MK-4827 exhibits nanomolar IC₅₀ values (3.8 nM for PARP-1, 2.1 nM for PARP-2) in biochemical assays, underpinning its high potency. Normal epithelial cells show resistance at micromolar concentrations, indicating a wide therapeutic index [APExBIO]. This selectivity is critical for minimizing off-target toxicity in translational and preclinical models.

Evidence & Benchmarks

• MK-4827 inhibits PARP-1 with an IC₅₀ of 3.8 nM and PARP-2 with an IC₅₀ of 2.1 nM, as measured in enzyme activity assays (APExBIO datasheet, link).
• BRCA-1 and BRCA-2 mutant cancer cell lines exhibit CC₅₀ values in the 10–100 nM range for MK-4827, while normal epithelial cells are resistant at >1 μM (APExBIO, link).
• In vivo, MK-4827 demonstrates significant tumor growth inhibition in BRCA-1 mutant MDA-MB-436 breast cancer and p53-deficient lung cancer xenograft models (PCI32765.com, link).
• Combination of all-trans retinoic acid (ATRA) with Niraparib overcomes cisplatin-induced PARP inhibitor resistance and improves survival in epithelial ovarian cancer models (Mei et al., 2024, link).
• MK-4827 enhances radiotherapy efficacy in preclinical models and demonstrates good tolerability and minimal toxicity at efficacious doses (Doripenemhydrate.com, link).
• Solubility is ≥32 mg/mL in DMSO and ≥50.9 mg/mL in ethanol (gentle warming), but the compound is insoluble in water (APExBIO, link).

This article extends the foundational overview in MK-4827 (Niraparib): Selective PARP Inhibitor for BRCA-Mutant and DNA Repair-Deficient Cancer Research by focusing on the latest resistance-overcoming strategies and precise workflow parameters for translational studies. It also clarifies the mechanistic advances presented in Strategic Horizons in PARP Inhibition by detailing new combinatorial data and bench-to-bedside translation. For a comprehensive summary of solubility and in vivo benchmarks, see MK-4827 (Niraparib): Selective PARP Inhibitor for BRCA-Mutant Cancer Research, which this article updates with new resistance and workflow insights.

Applications, Limits & Misconceptions

MK-4827 is widely used for:

• Investigating DNA damage response pathways in cancer research.
• Cell proliferation and viability assays in BRCA-mutant and DNA repair-deficient cell lines.
• Radiosensitization studies in preclinical tumor models.
• Combination therapy explorations, especially with agents like ATRA and platinum-based chemotherapeutics (Mei et al., 2024).

However, its selectivity for PARP-1/-2 means that tumors with restored homologous recombination or certain resistance mechanisms may not respond. Not all PARP inhibitor resistance is overcome by switching agents; cross-resistance can occur. MK-4827 is research-use only and not approved for human therapeutic use outside clinical trials. Long-term solution storage is not recommended due to potential compound degradation.

Common Pitfalls or Misconceptions

• MK-4827 is not effective in cancer cells with functional homologous recombination or wild-type BRCA-1/2.
• Solubility in water is extremely limited (<0.1 mg/mL); improper dissolution can impair assay reproducibility.
• Resistance to one PARP inhibitor often confers resistance to others, including MK-4827, especially after platinum-based chemotherapy (Mei et al., 2024).
• MK-4827 should not be used as a surrogate for all PARP inhibitors; selectivity and off-target profiles may differ.
• It is not suitable for direct clinical administration; for research use only.

Workflow Integration & Parameters

MK-4827 (A3617, APExBIO) is supplied as a solid, with a molecular weight of 320.39 and formula C₁₉H₂₀N₄O. For in vitro studies, dissolve in DMSO (≥32 mg/mL) or ethanol (≥50.9 mg/mL, gentle warming). Avoid water as a solvent. Recommended storage is at -20°C, protected from light; avoid long-term storage of solutions. Typical working concentrations are 10–100 nM for cancer cell lines with HRD, up to 1 μM for selectivity controls. For in vivo dosing, refer to established protocols in breast and ovarian cancer xenograft models (PCI32765.com). MK-4827 is compatible with cell proliferation, clonogenic survival, DNA damage foci, and caspase activation assays. For resistance studies, combination with ATRA or sequential platinum exposure is recommended as per recent reports (Mei et al., 2024).

Conclusion & Outlook

MK-4827 (Niraparib), distributed by APExBIO, remains a cornerstone tool for dissecting DNA repair pathway vulnerabilities in BRCA-mutant and DNA repair-deficient cancers. Its robust biochemical selectivity, well-characterized in vitro and in vivo benchmarks, and compatibility with advanced combination strategies—including radiosensitization and resistance-reversal—make it an essential agent for translational oncology workflows. Ongoing research into PARP inhibitor resistance, including combination with ATRA, continues to expand the utility of MK-4827 in overcoming therapeutic barriers in cancer research (Mei et al., 2024).